NCT06629818View on ClinicalTrials.gov

Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

October 14, 2026

Study Completion Date

October 14, 2026

Conditions
Light Chain (AL) Amyloidosis
Interventions
DRUG

Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous)

qw cycle 1-2, q2w cycle 3-6, q4w cycle 7-12

DRUG

Venetoclax

400mg po qd for 1 year

DRUG

Dexamethasone

Dexamethasone 20mg po qw for the first 6 months, then 10mg po qw for the next 6 months

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER